Sign in
Covance Inc.
Company Website

Research This Company


History
Vision
Services
Benefits
Contact
Diversity




In the late 1980s and early 1990s, Corning, Incorporated acquired numerous best-of-class drug development companies, some with roots dating back to the 1940s. In January 1997, Corning spun off these businesses as one publicly-traded, independent company called Covance Inc. [NYSE: CVD].


Covance Today

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.3 billion, global operations in more than 20 countries, and greater than 8,900 employees worldwide. Covance’s global capacity reaches the Americas, UK, Europe and Asia Pacific regions.

Covance’s expertise in toxicology, Phase I, research products, drug metabolism and pharmacokinetics helps clients maximize the chances of success in the clinical drug development phases. Covance’s clinical development services offer Phase II through IV clinical trials and post-marketing services.

As the industry leader in central laboratory services, Covance’s focus on automation and applied sciences links its scientific experience with state-of-the-art technology for DNA ad RNA extraction, alliquoting and banking.

Moving forward, Covance continues to broaden its capabilities by strategic acquisition and in-house development. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Jobs at Covance Inc.:

See All Jobs (22)


Company Quick Look
 
Ticker symbol: CVD
Number of employees: More than 8900
Year founded: 1980s
Primary Business: Biotechnology/ Pharmacay
 
Covance Inc.